Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) traded up 1.6% on Friday . The company traded as high as $7.17 and last traded at $6.91, with a volume of 607,755 shares traded. The stock had previously closed at $6.80.

A number of analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a research report on Tuesday. Maxim Group reissued a “buy” rating and issued a $15.00 price objective on shares of Anavex Life Sciences Corp. in a research report on Wednesday, June 22nd. Finally, FBR & Co reissued a “buy” rating on shares of Anavex Life Sciences Corp. in a research report on Wednesday, June 22nd.

The stock’s market cap is $252.11 million. The firm has a 50 day moving average price of $5.20 and a 200-day moving average price of $4.81.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last issued its quarterly earnings results on Wednesday, May 11th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.10. On average, equities research analysts predict that Anavex Life Sciences Corp. will post ($0.34) earnings per share for the current fiscal year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.